生物医药公司Puma Biotechnology最近宣布公司开发的一种抗癌药物neratinib在治疗HER2阳性乳腺癌的临床研究中药效超过了现有的Herceptin（曲妥珠单抗 Trastuzumab 赫赛汀）。根据公司披露的详细研究数据，当neratinib与化疗疗法联合治疗时患者的病例完全缓解率达到了39%，而Herceptin与化疗疗法联合治疗的病例完全缓解率仅为23%。而当使用者范围缩小为高危人群患者时，neratinib的这一数字则升至45%，对照组仅为29%。

Puma公司的这一临床二期结果是在本周一的美国癌症研究会上公布的，受此消息影响公司的股价也有小幅上升。这一结果也令Puma倍受鼓舞，目前公司正在着手进行这一药物的临床三期研究。

The biotech says that neratinib plus chemo achieved a pathological complete response rate of 39% among patients, compared to 23% taking a combination of Herceptin and chemo, according to a report from Reuters. And when you narrow the population down to a set of high-risk patients, the pCR rate was 45% compared to 29% for standard care.

Shares of Puma ($PBYI) surged ab0ut 5% on the news this morning.

The Phase II study data were revealed at the American Association for Cancer Research Meeting in San Diego on Monday. Puma CEO Alan Auerbach, who had earlier outlined top-line results for the drug, tells Reuters that the biotech is now designing a Phase III program for the HER2-positive patient group as well as the high-risk patients identified through genetic profiling.

One of the reasons Puma is closely watched is that its executive crew has been here before. Auerbach sold his other biotech cat--Cougar Biotechnology, which developed Zytiga--to Johnson & Johnson ($JNJ) in a billion-dollar deal. And he's back in the same development zone he was in when he did the highly successful Cougar deal.

免责声明： 

      本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。 

      如有侵权，请联系我们删除